Bristol Myers (BMY) Q2 EPS Jumps 36%
Bristol Myers Squibb (NYSE:BMY) is a leading biopharmaceutical company focused on innovative medicines in oncology, cardiovascular, immunology, and neuroscience. On July 31, 2025, it released results for the second quarter, reporting GAAP revenue and non-GAAP EPS that exceeded Wall Street expectations. The company achieved GAAP revenue of $12.269 billion, compared to an analyst estimate of $11.385 billion, and non-GAAP earnings per share (EPS) of $1.46, surpassing the estimated $1.07 per share. Despite the revenue beat and higher-than-expected profitability, year-over-year figures were pressured by legacy drug declines, margin compression, and a significant R expense. The company raised its full-year revenue guidance for 2025, but lowered its expected non-GAAP EPS range due to a $1.5 billion R charge stemming from a strategic deal with BioNTech. Management described the period as solid for new therapies and global expansion, but acknowledged ongoing headwinds from its mature product lines and a complex regulatory landscape.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Bristol Myers Squibb develops prescription drugs in areas like cancer, blood disorders, heart disease, immunology, and neuroscience. Its business centers on creating and marketing innovative therapies, including well-known products such as Opdivo for cancer, Eliquis for blood clots, and a new wave of medicines in cell therapy and immunology.
Source Fool.com
